Zhitong Finance APP learned that the British pharmaceutical group GSK (GSK. US) on Monday dismissed a report in the Mail on Sunday that GlaxoSmithKline may be interested in bidding for Aurinia Pharmaceuticals (AUPH. US)。
A spokesman for GlaxoSmithKline said the report was not true.
On October 22, some media quoted people familiar with the matter as saying that the American company BMY. US) expressed interest in acquiring Aurinia, and the company's shares rose nearly 27 percent as a result.
Since the news, the company's stock price has risen nearly 50% and its market capitalization is about $4.2 billion. As of Friday's U.S. stock close, Aurinia Pharmaceuticals was up 10.41 percent at $33.08.
Aurinia's drug Lupkynis is approved to treat a type of kidney inflammation caused by the autoimmune disease lupus erythematosus, and the company is working on other drugs to treat autoimmune diseases and kidney disease.
![Interview with GlaxoSke Chishin: With core competitiveness, we will steadily develop the Chinese market[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)